metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 9X8, 2024 Journal of Clinical Oncology J Immunother Cancer. 2024 Mar 13;12(3):e008409 NCT03414983	RCT	mCRC - 1st line (L1)	nivolumab plus mFOLFOX6 plus bevacizumab	mFOLFOX6 plus bevacizumab	Patients aged at least 18 years with histologically confirmed mCRC not amenable to curative resection and no prior chemotherapy for metastatic disease	127 / 68	low	inconclusive	inconclusive 19 % decrease in progression or deaths (PFS) (PE) The CheckMate 9X8 trial investigating first-line nivolumab plus SOC versus SOC in patients with mCRC did not meet its primary endpoint of PFS by BICR. Nivolumab plus SOC showed numerically higher PFS rates after 12 months, a higher response rate, and more durable responses compared with SOC alone, with acceptable safety
	METIMMOX, 2024 ASCO May 2021 Br J Cancer 130, 1921–1928 (2024) OncoImmunology, 13(1). NCT03388190	RCT	mCRC - 1st line (L1)	nivolumab plus SOC	SOC	previously untreated, unresectable metastatic colorectal, MSS, no upper age limit,	38 / 38	some concern	no results	no results The investigational regimen did not improve the primary outcome for the intention-to-treat population but might beneﬁt small subgroups of patients with previously untreated, metastatic microsatellite-stable colorectal cancer.